Clostridium symbiosum (C. symbiosum)

Clostridium symbiosum is a Gram-positive, anaerobic, spore-forming bacterium that is a common constituent of the human intestinal microbiota (Xie et al., 2017). Although it is typically a commensal organism, it has been identified as a highly specific fecal biomarker for the early detection of colorectal cancer (CRC) and its precursor, colorectal adenoma (Xie et al., 2017; Yachida et al., 2019). Research indicates that the abundance of C. symbiosum increases significantly during the progression from healthy tissue to adenoma and eventually to carcinoma, making it a valuable target for non-invasive diagnostic assays (Xie et al., 2017). Biologically, the organism is involved in the fermentation of various carbohydrates and plays a role in the metabolic transformation of bile acids within the gut lumen (NCBI Taxonomy). While not a traditional drug target like a receptor or enzyme, its population can be influenced by broad-spectrum antibiotics such as metronidazole or vancomycin, which are used to treat anaerobic infections (Finegold et al., 2005). In rare clinical scenarios, C. symbiosum has been implicated in opportunistic infections, including bacteremia and intra-abdominal abscesses, particularly in patients with compromised intestinal integrity (Brook, 2010). Understanding its role in the gut-cancer axis continues to be a primary focus of microbiome-based oncology research.

Other names

Lachnoclostridium symbiosum

As a whole organism, it is targeted by antibiotics which inhibit various bacterial processes such as cell wall synthesis, DNA replication, or protein synthesis (Finegold et al., 2005).